Cargando…

Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breast-conserving therapy?

BACKGROUND: In the post-Z0011 trial era, the need to perform surgical axillary staging for early-stage breast cancer patients, who are treated with breast-conserving therapy (BCT), is being questioned. We conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results (S...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jin, Tang, Hailin, Li, Xing, Song, Cailu, Xiong, Zhenchong, Wang, Xi, Xie, Xiaoming, Tang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505128/
https://www.ncbi.nlm.nih.gov/pubmed/31068224
http://dx.doi.org/10.1186/s40880-019-0371-y
_version_ 1783416695799414784
author Wang, Jin
Tang, Hailin
Li, Xing
Song, Cailu
Xiong, Zhenchong
Wang, Xi
Xie, Xiaoming
Tang, Jun
author_facet Wang, Jin
Tang, Hailin
Li, Xing
Song, Cailu
Xiong, Zhenchong
Wang, Xi
Xie, Xiaoming
Tang, Jun
author_sort Wang, Jin
collection PubMed
description BACKGROUND: In the post-Z0011 trial era, the need to perform surgical axillary staging for early-stage breast cancer patients, who are treated with breast-conserving therapy (BCT), is being questioned. We conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the safety of waiving surgical axillary staging in patients with T1 breast cancer treated with BCT. METHODS: A total of 166,615 eligible patients diagnosed between 2000 and 2012 were divided into staging (sentinel lymph node biopsy or axillary lymph node dissection) and non-staging (no lymph node examined or only needle aspiration biopsy of lymph nodes) groups. Propensity score matching (PSM) was performed to balance disparities between the two groups. Multivariate analysis with the Cox proportional hazards model was used to assess factors related to breast cancer-specific survival (BCSS). RESULTS: Although the tumor size at time of presentation was decreasing over years, the rate of surgical axillary staging increased from 93.3% to 96.9%. The 5-year BCSS rates of the whole cohort (before PSM) and matched cohort (after PSM) were 98.0% and 97.5%. Within the matched cohort, the BCSS was significantly longer in the staging group than in the non-staging group (P < 0.001). However, surgical axillary staging did not benefit patients who were 50–79 years old, had tumor size < 1 cm, histological grade I disease, or favorable histological types (tubular/mucinous/papillary) in stratified analyses (P > 0.05). Race, marital status, hormone receptors, and chemotherapy were not associated with the favorable impact of surgical axillary staging on BCSS (P > 0.05). CONCLUSION: Although surgical axillary staging remains important for T1 breast cancer patients treated with BCT, it might be unnecessary for patients with old age, small tumor, grade I disease, or favorable histological types. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40880-019-0371-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6505128
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65051282019-05-13 Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breast-conserving therapy? Wang, Jin Tang, Hailin Li, Xing Song, Cailu Xiong, Zhenchong Wang, Xi Xie, Xiaoming Tang, Jun Cancer Commun (Lond) Original Article BACKGROUND: In the post-Z0011 trial era, the need to perform surgical axillary staging for early-stage breast cancer patients, who are treated with breast-conserving therapy (BCT), is being questioned. We conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the safety of waiving surgical axillary staging in patients with T1 breast cancer treated with BCT. METHODS: A total of 166,615 eligible patients diagnosed between 2000 and 2012 were divided into staging (sentinel lymph node biopsy or axillary lymph node dissection) and non-staging (no lymph node examined or only needle aspiration biopsy of lymph nodes) groups. Propensity score matching (PSM) was performed to balance disparities between the two groups. Multivariate analysis with the Cox proportional hazards model was used to assess factors related to breast cancer-specific survival (BCSS). RESULTS: Although the tumor size at time of presentation was decreasing over years, the rate of surgical axillary staging increased from 93.3% to 96.9%. The 5-year BCSS rates of the whole cohort (before PSM) and matched cohort (after PSM) were 98.0% and 97.5%. Within the matched cohort, the BCSS was significantly longer in the staging group than in the non-staging group (P < 0.001). However, surgical axillary staging did not benefit patients who were 50–79 years old, had tumor size < 1 cm, histological grade I disease, or favorable histological types (tubular/mucinous/papillary) in stratified analyses (P > 0.05). Race, marital status, hormone receptors, and chemotherapy were not associated with the favorable impact of surgical axillary staging on BCSS (P > 0.05). CONCLUSION: Although surgical axillary staging remains important for T1 breast cancer patients treated with BCT, it might be unnecessary for patients with old age, small tumor, grade I disease, or favorable histological types. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40880-019-0371-y) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-08 /pmc/articles/PMC6505128/ /pubmed/31068224 http://dx.doi.org/10.1186/s40880-019-0371-y Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Article
Wang, Jin
Tang, Hailin
Li, Xing
Song, Cailu
Xiong, Zhenchong
Wang, Xi
Xie, Xiaoming
Tang, Jun
Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breast-conserving therapy?
title Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breast-conserving therapy?
title_full Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breast-conserving therapy?
title_fullStr Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breast-conserving therapy?
title_full_unstemmed Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breast-conserving therapy?
title_short Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breast-conserving therapy?
title_sort is surgical axillary staging necessary in women with t1 breast cancer who are treated with breast-conserving therapy?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505128/
https://www.ncbi.nlm.nih.gov/pubmed/31068224
http://dx.doi.org/10.1186/s40880-019-0371-y
work_keys_str_mv AT wangjin issurgicalaxillarystagingnecessaryinwomenwitht1breastcancerwhoaretreatedwithbreastconservingtherapy
AT tanghailin issurgicalaxillarystagingnecessaryinwomenwitht1breastcancerwhoaretreatedwithbreastconservingtherapy
AT lixing issurgicalaxillarystagingnecessaryinwomenwitht1breastcancerwhoaretreatedwithbreastconservingtherapy
AT songcailu issurgicalaxillarystagingnecessaryinwomenwitht1breastcancerwhoaretreatedwithbreastconservingtherapy
AT xiongzhenchong issurgicalaxillarystagingnecessaryinwomenwitht1breastcancerwhoaretreatedwithbreastconservingtherapy
AT wangxi issurgicalaxillarystagingnecessaryinwomenwitht1breastcancerwhoaretreatedwithbreastconservingtherapy
AT xiexiaoming issurgicalaxillarystagingnecessaryinwomenwitht1breastcancerwhoaretreatedwithbreastconservingtherapy
AT tangjun issurgicalaxillarystagingnecessaryinwomenwitht1breastcancerwhoaretreatedwithbreastconservingtherapy